Sarmad Sadeghi is an Oncology physician affiliated with University of Southern California. OpenAlex indexes 106 publications with 538 citations (h-index 13); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1441 Eastlake Ave
Nor 8302e
Los Angeles, CA 900890112
Telephone
323-865-3000Provider last certified this registry record 31 Oct 2020.
Clinical trials
- Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Sponsor: Vasgene Therapeutics, Inc
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
Sponsor: National Cancer Institute (NCI)
- A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
Sponsor: Vasgene Therapeutics, Inc
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20241 payment
- PFIZER INC.Program year20231 payment
- PFIZER INC.Program year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Androgen Receptor Inhibitor100%Xtandi100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2026 per NIH RePORTER. The latest:
- Synergistic immune response after EphrinB2 inhibition & PD-1 antibody therapy in urothelial carcinoma.
University of Southern California
FY2026$679,846R01CA293348 - Synergistic immune response after EphrinB2 inhibition & PD-1 antibody therapy in urothelial carcinoma.
University of Southern California
FY2025$712,735R01CA293348
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
David Liebeskind, MD
University of Southern California
Lon Schneider, MD
University of Southern California
Amytis Towfighi, MD
University of Southern California
Norah Terrault, MD
University of Southern California
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”